On September 3, 2026 Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer, autoimmune, and inflammatory diseases, reported that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, at the Lotte New York Palace Hotel in New York City.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details on the presentation are as follows:
Date: Wednesday, September 16th, 2026
Time: 12:00 PM – 12:30 PM (Eastern Standard Time)
Location: Lotte New York Palace Hotel, Kennedy II, 4th Floor
Webcast Link: View Source
Webcast and replay information for this event will also be available on the investor relations section of Medicenna’s website on the Events & Presentations page. The webcast will be available for 90 days.
To schedule a one-on-one investor meeting with Dr. Fahar Merchant, please register for the conference or contact your H.C. Wainwright representative.
(Press release, Medicenna Therapeutics, SEP 3, 2026, https://www.globenewswire.com/news-release/2026/09/03/3355762/0/en/medicenna-to-present-at-the-h-c-wainwright-28th-annual-global-investment-conference.html [SID1234670591])